pharma · Rheumatoid Arthritis · Warm Antibody Autoimmune Hemolytic Anemia · RIGL
RIGEL PHARMACEUTICALS
RIGEL PHARMACEUTICALS INC
RIGEL PHARMACEUTICALS clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1180 Veterans Blvd, South San Francisco, CA 94080, US
- Founded
- 1996
- Employees
- 286
- Programs
- 36
- Drugs
- 26
- Patents
- 373
RIGEL PHARMACEUTICALS projects
4 ClinicalTrials.gov programs sponsored by RIGEL PHARMACEUTICALS.
RIGEL PHARMACEUTICALS has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Fostamatinib
RIGEL PHARMACEUTICALS INC
Chronic Graft Versus Host Disease
1 trial -
Fostamatinib 100 mg bid and Paclitaxel
RIGEL PHARMACEUTICALS INC
Ovarian Cancer
1 trial -
Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
RIGEL PHARMACEUTICALS INC
Pancreatic Ductal Adenocarcinoma (PDAC)
1 trial -
Olutasidenib Investigational Agent Administration
RIGEL PHARMACEUTICALS INC
Acute Myeloid Leukemia
1 trial
Frequently asked questions
How many clinical projects does RIGEL PHARMACEUTICALS have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.